UNSPSC 51101600: Amebicides and trichomonacides

This classification denotes drugs that destroy amebae or protozoans, parasitic organisms, and species thereof which cause amebiasis in man and animal. Amebae are organisms that evince a vesicular nucleus and formation of several lodopodia, one of which is dominant at a given time, and which reproduce asexually by binary fission. Such organsms give rise to afflictions such as acanthamoeba keratitis, blastocystis, amebic dysentery, entamoebiasis, and amebic liver abscess, or cause central nervous system parasitic infections, helminthiasis, mesomycetozoea infections, and parasitemia.

UNSPSC 51101600 Amebicides and trichomonacides, a Class code, does not reflect the scope of work state and local governments are actually buying under recent opportunities tagged to this code. The three recent solicitations show state and local agencies procuring naloxone and drug deactivation systems, medical and first aid supplies for fire rescue operations, and generic pharmaceuticals and over-the-counter products through cooperative purchasing — none of which align with the code's nominal focus on amebicide and trichomonacide drugs. The issuing bodies include county health departments, municipal fire services, state health commissions, and multi-state cooperative purchasing alliances. This code appears to carry significant tag misalignment in state and local procurement systems.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (due July 26, 2023, posted June 30, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually for the Seminole County Community Health Building. The City of Tampa issued an IFB (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a $700,000 estimated contract amount and a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued an RFI (posted April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, through MMCAP, issued an RFP (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026.